Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Hereditary Angioedema Therapeutic Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global hereditary angioedema therapeutic market is expected to exhibit a CAGR of 8.79% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to a deficiency of a blood protein. It also leads to fluid leakage due to the constant accumulation of liquids outside the veins of hands, feet, intestinal wall, genitals, face, tongue, and larynx. At present, there is a rise in the demand for hereditary angioedema therapeutics due to the growing advancements in novel therapeutics across the globe.

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Hereditary Angioedema Therapeutic Market Trends:

There is presently a considerable increase in the prevalence of HAE among individuals due to a lack of C1 protein. As a result, there is a rise in the demand for HAE therapeutics around the world. This, along with the growing awareness among the masses about the treatment of HAE, represents one of the key factors driving the market. Moreover, key market players are extensively investing in research and development (R&D) activities to enhance orphan drug development. This, coupled with the escalating demand for subcutaneous injections that are highly effective in administering medications, such as insulin, morphine, diacetylmorphine and goserelin, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to facilitate faster diagnosis and provide optimal standards of treatment and care to patients. In line with this, rising incidences of genetic mutations leading to the disorder are positively influencing the market. Besides this, the escalating demand for preventive medical care to avoid future illness and treatment is offering lucrative growth opportunities to industry investors. Apart from this, the burgeoning healthcare industry is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hereditary angioedema therapeutic market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, drug class, treatment type, route of administration and end user.

Breakup by Type:

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Type I Hereditary Angioedema
  • Type II Hereditary Angioedema
  • Type III Hereditary Angioedema
     

Breakup by Drug Class:

  • C1-Esterase Inhibitor
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others
     

Breakup by Treatment Type:

  • Prophylaxis Treatment
  • On-demand Treatment
     

Breakup by Route of Administration:

  • Intravenous
  • Subcutaneous
  • Oral
     

Breakup by End User:

  • Hospitals
  • Clinics
  • Home Healthcare
  • Others
     

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Type, Drug Class, Treatment Type, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Hereditary Angioedema Therapeutic Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    Type I Hereditary Angioedema
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Type II Hereditary Angioedema
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Type III Hereditary Angioedema
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by Drug Class
    7.1    C1-Esterase Inhibitor
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Bradykinin B2 Receptor Antagonist
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Kallikrein Inhibitor
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Others
        7.4.1 Market Trends
        7.4.2 Market Forecast
8    Market Breakup by Treatment Type
    8.1    Prophylaxis Treatment
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    On-demand Treatment
        8.2.1 Market Trends
        8.2.2 Market Forecast
9    Market Breakup by Route of Administration
    9.1    Intravenous
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Subcutaneous
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Oral
        9.3.1 Market Trends
        9.3.2 Market Forecast
10    Market Breakup by End User
    10.1    Hospitals
        10.1.1 Market Trends
        10.1.2 Market Forecast
    10.2    Clinics
        10.2.1 Market Trends
        10.2.2 Market Forecast
    10.3    Home Healthcare
        10.3.1 Market Trends
        10.3.2 Market Forecast
    10.4    Others
        10.4.1 Market Trends
        10.4.2 Market Forecast
11    Market Breakup by Region
    11.1    North America
        11.1.1 United States
           11.1.1.1 Market Trends
           11.1.1.2 Market Forecast
        11.1.2 Canada
           11.1.2.1 Market Trends
           11.1.2.2 Market Forecast
    11.2    Asia-Pacific
        11.2.1 China
           11.2.1.1 Market Trends
           11.2.1.2 Market Forecast
        11.2.2 Japan
           11.2.2.1 Market Trends
           11.2.2.2 Market Forecast
        11.2.3 India
           11.2.3.1 Market Trends
           11.2.3.2 Market Forecast
        11.2.4 South Korea
           11.2.4.1 Market Trends
           11.2.4.2 Market Forecast
        11.2.5 Australia
           11.2.5.1 Market Trends
           11.2.5.2 Market Forecast
        11.2.6 Indonesia
           11.2.6.1 Market Trends
           11.2.6.2 Market Forecast
        11.2.7 Others
           11.2.7.1 Market Trends
           11.2.7.2 Market Forecast
    11.3    Europe
        11.3.1 Germany
           11.3.1.1 Market Trends
           11.3.1.2 Market Forecast
        11.3.2 France
           11.3.2.1 Market Trends
           11.3.2.2 Market Forecast
        11.3.3 United Kingdom
           11.3.3.1 Market Trends
           11.3.3.2 Market Forecast
        11.3.4 Italy
           11.3.4.1 Market Trends
           11.3.4.2 Market Forecast
        11.3.5 Spain
           11.3.5.1 Market Trends
           11.3.5.2 Market Forecast
        11.3.6 Russia
           11.3.6.1 Market Trends
           11.3.6.2 Market Forecast
        11.3.7 Others
           11.3.7.1 Market Trends
           11.3.7.2 Market Forecast
    11.4    Latin America
        11.4.1 Brazil
           11.4.1.1 Market Trends
           11.4.1.2 Market Forecast
        11.4.2 Mexico
           11.4.2.1 Market Trends
           11.4.2.2 Market Forecast
        11.4.3 Others
           11.4.3.1 Market Trends
           11.4.3.2 Market Forecast
    11.5    Middle East and Africa
        11.5.1 Market Trends
        11.5.2 Market Breakup by Country
        11.5.3 Market Forecast
12    SWOT Analysis
    12.1    Overview
    12.2    Strengths
    12.3    Weaknesses
    12.4    Opportunities
    12.5    Threats
13    Value Chain Analysis
14    Porters Five Forces Analysis

    14.1    Overview
    14.2    Bargaining Power of Buyers
    14.3    Bargaining Power of Suppliers
    14.4    Degree of Competition
    14.5    Threat of New Entrants
    14.6    Threat of Substitutes
15    Price Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Key Players
    16.3    Profiles of Key Players
        16.3.1    Adverum Biotechnologies Inc.
           16.3.1.1 Company Overview
           16.3.1.2 Product Portfolio
           16.3.1.3 Financials
        16.3.2    Amgen Inc.
           16.3.2.1 Company Overview
           16.3.2.2 Product Portfolio
           16.3.2.3 Financials
           16.3.2.4 SWOT Analysis
        16.3.3    Attune Pharmaceuticals
           16.3.3.1 Company Overview
           16.3.3.2 Product Portfolio
        16.3.4    BioCryst Pharmaceuticals Inc.
           16.3.4.1 Company Overview
           16.3.4.2 Product Portfolio
           16.3.4.3 Financials
           16.3.4.4 SWOT Analysis
        16.3.5    Centogene N.V.
           16.3.5.1 Company Overview
           16.3.5.2 Product Portfolio
           16.3.5.3 Financials
        16.3.6    CSL Limited
           16.3.6.1 Company Overview
           16.3.6.2 Product Portfolio
           16.3.6.3 Financials
           16.3.6.4 SWOT Analysis
        16.3.7    Ionis Pharmaceuticals Inc.
           16.3.7.1 Company Overview
           16.3.7.2 Product Portfolio
           16.3.7.3 Financials
           16.3.7.4 SWOT Analysis
        16.3.8    KalVista Pharmaceuticals Inc.
           16.3.8.1 Company Overview
           16.3.8.2 Product Portfolio
           16.3.8.3 Financials
        16.3.9    Novartis AG
           16.3.9.1 Company Overview
           16.3.9.2 Product Portfolio
           16.3.9.3 Financials
           16.3.9.4 SWOT Analysis
        16.3.10    Pharming Group N.V.
           16.3.10.1 Company Overview
           16.3.10.2 Product Portfolio
           16.3.10.3 Financials
        16.3.11    Sanofi S.A.
           16.3.11.1 Company Overview
           16.3.11.2 Product Portfolio
           16.3.11.3 Financials
        16.3.12    Takeda Pharmaceutical Company Limited
           16.3.12.1 Company Overview
           16.3.12.2 Product Portfolio
           16.3.12.3 Financials
           16.3.12.4 SWOT Analysis

List of Figures

Figure 1: Global: Hereditary Angioedema Therapeutic Market: Major Drivers and Challenges
Figure 2: Global: Hereditary Angioedema Therapeutic Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hereditary Angioedema Therapeutic Market: Breakup by Type (in %), 2021
Figure 5: Global: Hereditary Angioedema Therapeutic Market: Breakup by Drug Class (in %), 2021
Figure 6: Global: Hereditary Angioedema Therapeutic Market: Breakup by Treatment Type (in %), 2021
Figure 7: Global: Hereditary Angioedema Therapeutic Market: Breakup by Route of Administration (in %), 2021
Figure 8: Global: Hereditary Angioedema Therapeutic Market: Breakup by End User (in %), 2021
Figure 9: Global: Hereditary Angioedema Therapeutic Market: Breakup by Region (in %), 2021
Figure 10: Global: Hereditary Angioedema Therapeutic (Type I Hereditary Angioedema) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Hereditary Angioedema Therapeutic (Type I Hereditary Angioedema) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Hereditary Angioedema Therapeutic (Type II Hereditary Angioedema) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Hereditary Angioedema Therapeutic (Type II Hereditary Angioedema) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Hereditary Angioedema Therapeutic (Type III Hereditary Angioedema) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Hereditary Angioedema Therapeutic (Type III Hereditary Angioedema) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Hereditary Angioedema Therapeutic (C1-Esterase Inhibitor) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Hereditary Angioedema Therapeutic (C1-Esterase Inhibitor) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Hereditary Angioedema Therapeutic (Bradykinin B2 Receptor Antagonist) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Hereditary Angioedema Therapeutic (Bradykinin B2 Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Hereditary Angioedema Therapeutic (Kallikrein Inhibitor) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Hereditary Angioedema Therapeutic (Kallikrein Inhibitor) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Hereditary Angioedema Therapeutic (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Hereditary Angioedema Therapeutic (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Hereditary Angioedema Therapeutic (Prophylaxis Treatment) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Hereditary Angioedema Therapeutic (Prophylaxis Treatment) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Hereditary Angioedema Therapeutic (On-demand Treatment) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Hereditary Angioedema Therapeutic (On-demand Treatment) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Hereditary Angioedema Therapeutic (Intravenous) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Hereditary Angioedema Therapeutic (Intravenous) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Hereditary Angioedema Therapeutic (Subcutaneous) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Hereditary Angioedema Therapeutic (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Hereditary Angioedema Therapeutic (Oral) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Hereditary Angioedema Therapeutic (Oral) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Hereditary Angioedema Therapeutic (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Hereditary Angioedema Therapeutic (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Global: Hereditary Angioedema Therapeutic (Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Global: Hereditary Angioedema Therapeutic (Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Global: Hereditary Angioedema Therapeutic (Home Healthcare) Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Global: Hereditary Angioedema Therapeutic (Home Healthcare) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Global: Hereditary Angioedema Therapeutic (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Global: Hereditary Angioedema Therapeutic (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: North America: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: North America: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: United States: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: United States: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Canada: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Canada: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Asia-Pacific: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Asia-Pacific: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: China: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: China: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Japan: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Japan: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: India: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: India: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: South Korea: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: South Korea: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Australia: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Australia: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Indonesia: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Indonesia: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Others: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Others: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Europe: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Europe: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Germany: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Germany: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: France: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: France: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: United Kingdom: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: United Kingdom: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Italy: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Italy: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Spain: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Spain: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Russia: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Russia: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Others: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Others: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Latin America: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Latin America: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Brazil: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Brazil: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Mexico: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 85: Mexico: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 86: Others: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 87: Others: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 88: Middle East and Africa: Hereditary Angioedema Therapeutic Market: Sales Value (in Million US$), 2016 & 2021
Figure 89: Middle East and Africa: Hereditary Angioedema Therapeutic Market: Breakup by Country (in %), 2021
Figure 90: Middle East and Africa: Hereditary Angioedema Therapeutic Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 91: Global: Hereditary Angioedema Therapeutic Industry: SWOT Analysis
Figure 92: Global: Hereditary Angioedema Therapeutic Industry: Value Chain Analysis
Figure 93: Global: Hereditary Angioedema Therapeutic Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hereditary Angioedema Therapeutic Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 4: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by Treatment Type (in Million US$), 2022-2027
Table 5: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 6: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 7: Global: Hereditary Angioedema Therapeutic Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 8: Global: Hereditary Angioedema Therapeutic Market: Competitive Structure
Table 9: Global: Hereditary Angioedema Therapeutic Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

We expect the global hereditary angioedema therapeutic market to exhibit a CAGR of 8.79% during 2022-2027.

The high prevalence of HAE among individuals owing to the lack of C1 protein, coupled with the growing cases of genetic mutations, are primarily driving the global hereditary angioedema therapeutic market.

The sudden outbreak of the COVID-19 pandemic had led to postponement of elective hereditary angioedema treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for hereditary angioedema therapeutics.

Based on the type, the global hereditary angioedema therapeutic market can be divided into type I hereditary angioedema, type II hereditary angioedema, and type III hereditary angioedema. Currently, type I hereditary angioedema holds the majority of the global market share.

Based on the drug class, the global hereditary angioedema therapeutic market has been segregated into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Among these, C1-esterase inhibitor currently accounts for the largest market share.

Based on the treatment type, the global hereditary angioedema therapeutic market can be categorized into prophylaxis treatment and on-demand treatment. Currently, on-demand treatment exhibits a clear dominance in the market.

Based on the route of administration, the global hereditary angioedema therapeutic market has been segmented into intravenous, subcutaneous, and oral, where intravenous currently accounts for the largest market share.

Based on the end user, the global hereditary angioedema therapeutic market can be bifurcated into hospitals, clinics, home healthcare, and others. Currently, hospitals hold the majority of the total market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global hereditary angioedema therapeutic market include Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4